about
The influence of genetic and environmental factors among MDMA users in cognitive performanceClinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT)Epigenetics and nutrition-related epidemics of metabolic diseases: Current perspectives and challenges.Computer-aided discovery of biological activity spectra for anti-aging and anti-cancer olive oil oleuropeins.BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and responseThe nutritional phenome of EMT-induced cancer stem-like cellsActive transmembrane drug transport in microgravity: a validation study using an ABC transporter model.Activation of the methylation cycle in cells reprogrammed into a stem cell-like state.Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.Accelerated geroncogenesis in hereditary breast-ovarian cancer syndromeSilibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivoThe anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancerMitophagy-driven mitochondrial rejuvenation regulates stem cell fateNeurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestionResponse of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibininNuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells.Germline BRCA1 mutation reprograms breast epithelial cell metabolism towards mitochondrial-dependent biosynthesis: evidence for metformin-based "starvation" strategies in BRCA1 carriers.Suppression of endogenous lipogenesis induces reversion of the malignant phenotype and normalized differentiation in breast cancer.Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway.Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users.STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.Exploring the Process of Energy Generation in Pathophysiology by Targeted Metabolomics: Performance of a Simple and Quantitative Method.Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.Oncometabolic Nuclear Reprogramming of Cancer Stemness.IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile.Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment.The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells.Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.Metformin targets histone acetylation in cancer-prone epithelial cells.Metabostemness: Metaboloepigenetic reprogramming of cancer stem-cell functions.5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study.
P50
Q28477994-B40024BC-2C53-4D60-B1BB-3EAB50D40F89Q28484562-E677FAFB-7AD2-46DC-B6C5-372E6C7F7882Q30248563-9C857021-2ECA-4EE4-87FD-AD5F88C95D6FQ30861997-E59D27B8-4779-4944-9EDA-8F128AC37FC9Q33798713-3947CCB9-0218-40BF-801C-B8FFF565DB2EQ33903933-C3A92807-EC00-4673-86E5-527E96AF3D81Q34100815-AF6520C4-1168-428C-A903-E33443A6B9AFQ34688384-8A68F15C-7B8A-4359-9E14-676E78D12444Q36527529-D6D1572B-D85A-4E17-B1DE-85B6A8124F1EQ36544839-699905C7-DE53-4CAB-9F6C-0809709496AAQ36781090-F138118A-552B-433C-8B75-AD72AF10789DQ36927785-34781F6C-F499-4815-AA85-8986A38A9B3DQ37022075-B2295A48-B052-4BE6-8B63-4F873BF3613DQ37107787-4256D398-5D98-4EF9-8708-CB8FF11930A3Q37111104-26C07D61-A086-48F1-8C66-F4E469C04D33Q37194210-B506F0A3-2ABC-4B75-9DDE-FC398B11F791Q37233828-CB7019D7-BB71-46DC-9C86-C9CBCE838757Q37362587-6700D628-936A-437E-91A9-EFD6438A0C88Q37420064-89E7CFF9-8DE1-4DAE-8E81-8B16ADE1C5AEQ37530247-E0B8697B-9D5E-4E7C-B9D9-D51F38B01777Q37619695-BF627738-D5AD-43A0-B7F5-CFABF7D6B6A0Q37687587-3A74B3A9-07B8-4C6E-957E-AD4B4F39B513Q38218285-E514DBEE-1F0F-458E-BB4E-701F102780E3Q38297935-F0924FE4-417A-4FAA-8696-6C2F729F5BDBQ38376332-1C1BD3D6-206D-4B60-92CD-94B47E71D03AQ38740295-C245D28D-0273-4EA7-BF83-41BE9411C615Q38834406-C40B3A80-6F22-4C7A-9C7D-5F22D6145566Q38874166-DF53A8FC-C23E-4273-9944-4B607B8816D4Q38951334-31FE4215-051D-4B5B-B8AF-65E15AD0F7AAQ39101764-D5AAB6B1-B37B-4FA1-AA8C-286F97A8E2E3Q39115260-07C14A45-DD01-4E8D-B6CA-52E9E7064D19Q39247899-46D4E2EB-96BF-46A5-B510-19B83EAE8C27Q40720253-B72AB4A7-AEE8-40E3-B5B4-675BA624CA02Q41831013-BC21DEB9-B4BA-47AA-8EB4-07CE7506C6FEQ41878464-C420CF33-0391-4C17-8731-0373F08CAE63Q42316814-55A25D9B-78DD-4198-BE56-11DC4CD4B453Q42508259-2AFB4318-E8AF-492C-A502-80B4287B77F9Q42983569-DAED85E6-7DBA-4353-A5B7-85746D3C69A9Q43116430-5F984F05-62F6-463E-B341-2AF8FD77CBF1Q43251705-21228055-0610-4455-A61A-5DC1A638F658
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elisabet Cuyàs
@ast
Elisabet Cuyàs
@en
Elisabet Cuyàs
@es
Elisabet Cuyàs
@fr
Elisabet Cuyàs
@sl
type
label
Elisabet Cuyàs
@ast
Elisabet Cuyàs
@en
Elisabet Cuyàs
@es
Elisabet Cuyàs
@fr
Elisabet Cuyàs
@sl
prefLabel
Elisabet Cuyàs
@ast
Elisabet Cuyàs
@en
Elisabet Cuyàs
@es
Elisabet Cuyàs
@fr
Elisabet Cuyàs
@sl
P106
P1153
56144861200
P21
P31
P496
0000-0001-5353-440X